Background: Identification of lymph nodes (LNs) draining a specific site or in obese macaques can be challenging.
Methods: Indocyanine Green (ICG) was administered intradermal (ID), intramuscular, in the oral mucosa, or subserosal in the colon followed by Near Infrared (NIR) imaging.
Results: After optimization to maximize LN identification, intradermal ICG was successful in identifying 50-100% of the axillary/inguinal LN at a site. Using NIR, collection of peripheral and mesenteric LNs in obese macaques was 100% successful after traditional methods failed. Additionally, guided collection of LNs draining the site of intraepithelial or intramuscular immunization demonstrated significantly increased numbers of T follicular helper (Tfh) cells in germinal centers of draining compared to nondraining LNs.
Conclusion: These imaging techniques optimize our ability to evaluate immune changes within LNs over time, even in obese macaques. This approach allows for targeted serial biopsies that permit confidence that draining LNs are being harvested throughout the study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474636 | PMC |
| http://dx.doi.org/10.1111/jmp.12605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of LY3324954 a long-acting glucagon-receptor agonist.
Mol Metab
January 2025
Comprehensive Diabetes Center and Department of Medicine - Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:
Article Synopsis
- * Researchers developed a new glucagon receptor agonist, LY3324954, that has better potency and effectiveness compared to regular glucagon, and it showed a prolonged impact in various animal models.
- * In tests, LY3324954 led to increased energy expenditure, weight loss, and better fat management in diet-induced obese mice, indicating its potential as a therapeutic option for obesity-related conditions.
The Rhesus Macaque as an Animal Model for Human Nutrition: An Ecological-Evolutionary Perspective.
Annu Rev Anim Biosci
November 2024
1Centre for Nutritional Ecology, Centre for Sport Nutrition and Health, School of Physical Education (Main Campus), Zhengzhou University, Zhengzhou, Henan, China.
Nutrition is a complex and contested area in biomedicine, which requires diverse evidence sources. Nonhuman primate models are considered an important biomedical research tool because of their biological similarities to humans, but they are typically used with little explicit consideration of their ecology and evolution. Using the rhesus macaque (RM), we consider the potential of nutritional ecology for enriching the use of primates as models for human nutrition.
View Article and Find Full Text PDFNK2R control of energy expenditure and feeding to treat metabolic diseases.
Nature
November 2024
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Article Synopsis
- - The study highlights the potential of activating the neurokinin 2 receptor (NK2R) as a dual approach to combat obesity and type 2 diabetes by suppressing appetite and increasing energy expenditure, representing a significant advancement over current multi-drug strategies.
- - Researchers developed long-acting NK2R agonists that can be administered weekly, which showed promising results in mice, leading to weight loss and improved insulin sensitivity without relying on traditional leptin signaling.
- - In tests with diabetic, obese macaques, NK2R activation resulted in substantial reductions in body weight, blood glucose, and cholesterol levels, suggesting a single-target therapeutic option that enhances energy balance and addresses cardiometabolic issues across different species.
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Diabetes Obes Metab
February 2025
Eccogene Inc., Cambridge, Massachusetts, USA.
Aims: GLP-1 receptor agonists (GLP-1 RAs) are proven therapies for type 2 diabetes mellitus (T2DM) and overweight or obesity. We performed non-clinical and first-in-human (FIH) evaluation of ECC5004/AZD5004, an oral small-molecule GLP-1 RA.
Materials And Methods: ECC5004 was profiled in cell lines overexpressing human GLP-1R, in glucose-stimulated insulin secretion (GSIS) assays in a human β-cell line and non-human primates (NHPs).
Toxicology profile of a novel GLP-1 receptor biased agonist-SAL0112 in nonhuman primates.
Toxicol Appl Pharmacol
November 2024
Biology Department, Pharmaron Inc., Beijing, China.
Article Synopsis
- Oral small-molecule GLP-1 receptor biased agonists like SAL0112 show promising results for treating type 2 diabetes and obesity, with strong efficacy observed in preclinical models.
- Preclinical toxicity studies on SAL0112 used various assays and cynomolgus monkeys to assess safety, revealing that it activates the monkey GLP-1 receptor effectively without significant cardiovascular impacts or serious side effects.
- The compound demonstrated moderate weight loss effects that were reversible, with a NOAEL of 150 mg/kg indicating a safe margin, supporting its advancement to clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!